Real life data about sofosbuvir, daclatasvir and ribavirin in the treatment of cirrhotic and non cirrhotic HCV patients

Zaghloul M. S.; Amer I. F.; El-Batee H.

首页> 外文期刊>Journal of viral hepatitis. >Real life data about sofosbuvir, daclatasvir and ribavirin in the treatment of cirrhotic and non cirrhotic HCV patients

【24h】

Real life data about sofosbuvir, daclatasvir and ribavirin in the treatment of cirrhotic and non cirrhotic HCV patients

机译：关于Sofosbuvir，Daclatasvir和利巴韦林治疗肝硬化和非肝硬化HCV患者的现实生活数据

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Journal of viral hepatitis.》 |2018年第s2期|共2页
作者
Zaghloul M. S.; Amer I. F.; El-Batee H.;
展开▼
作者单位

Kafrelsheikh Univ Fac Med Hepatol Gastroenterol &

Infect Dis Kafrelsheikh Egypt;

Kafrelsheikh Univ Fac Med Hepatol Gastroenterol &

Infect Dis Kafrelsheikh Egypt;

Kafrelsheikh Univ Fac Med Hepatol Gastroenterol &

Infect Dis Kafrelsheikh Egypt;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of generic daclatasvir +sofosbuvir ± ribavirin in treatment of genotype 3infected hepatitis C patients - a real life experience from Pakistan [J] . Muhammad Umar, Tayyab Saeed Akhter, Junaid Sadiq, 肝癌研究（英文版） . 2018,第011期
2. Efficacy and safety of generic daclatasvir +sofosbuvir ± ribavirin in treatment of genotype 3infected hepatitis C patients - a real life experience from Pakistan [J] . Muhammad Umar1, Tayyab Saeed Akhter1, Junaid Sadiq2, 肝癌研究(英文版) . 2018,第011期
3. Efficacy and Safety of Ombitasvir plus Paritaprevir,Ritonavir and Ribavirin in Non-cirrhotic Treatment-naive and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection [J] . Manar Ahmed, Azza E.Mansey, Engy A.Wahsh, 当代医学科学(英文) . 2021,第003期
4. P1‐105: Real life data about sofosbuvir, daclatasvir and ribavirin in the treatment of cirrhotic and non cirrhotic HCV patients [J] . Journal of viral hepatitis. . 2018,第S1期

机译：P1-105：关于Sofosbuvir，Daclatasvir和利巴韦林的真实生活数据在治疗Cirrhotic和非肝硬化HCV患者
5. Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV [J] . Zeng Q. -L., Li C. -X., Zhang D. -W., Alimentary pharmacology & therapeutics. . 2016,第7期

机译：信：索非布韦联合达卡他韦联合利巴韦林在中国治疗经验丰富的肝硬化基因型1b HCV患者中安全性和有效性12周
6. Prediction of SVR rates in HCV GT-3 non-cirrhotic patients with 8 weeks of Daclatasvir plus Sofosbuvir +/- Ribavirin treatment using a viral kinetics model [J] . Zhang J., Garimella T. S., Narasimhan P., Journal of pharmacokinetics and pharmacodynamics . 2016,第Suppla期

机译：使用病毒动力学模型预测达卡他韦+索非布韦+/-利巴韦林治疗8周的HCV GT-3非肝硬化患者的SVR率
7. Patients with HCV/HIV Co-infection Achieving a Sustained Virological Response Following HCV Treatment with Peginterferon alfa-2a (PEGASYS) plus Ribavirin (COPEGUS) have Improved Health Related Quality of Life [C] . D.T. Dieterich, M. Rodriguez Torres, J.K. Rockstroh International AIDS Conference . 2004

机译：HCV / HIV的患者在用Peginterferon Alfa-2a（Pegasys）加上利巴韦林（Copegegs）后HCV治疗后实现持续的病毒学反应，具有改善的健康相关的生活质量
8. Impact of Stent Type on Outcome of Cirrhotic Patients Treated with Transjugular Introhepatic Portosystemic Shunt [D] . Liu, Jiangtao. 2021

机译：支架类型对肝硬化血管内系统分流器治疗肝硬化患者结果的影响
9. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients [O] . Adriano Pellicelli, Vincenzo Messina, Valerio Giannelli, 2020

机译：平剂量利巴韦林加Sofosbuvir / Daclatasvir在基因型3肝硬化患者中的高疗效和安全性
10. Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV [O] . Q.-L. Zeng, C.-X. Li, D.-W. Zhang, 2016

机译：字母：Sofosbuvir Plus daclatasvir与利巴韦林的安全性和疗效在中药治疗中的12周龄肝硬化基因型1B患者HCV患者
11. Use of the Videophone to Collect Quality of Life Data from Burn Patients. [R] . Yoder, L. H., McFall, D. C., Cancio, L. C. 2012

机译：使用可视电话收集烧伤患者的生活质量数据。

Real life data about sofosbuvir, daclatasvir and ribavirin in the treatment of cirrhotic and non cirrhotic HCV patients

著录项

引文网络

相似文献

相关主题

期刊订阅